New Mexico Educational Retirement Board Purchases 2,900 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

New Mexico Educational Retirement Board lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 14.5% during the first quarter, Holdings Channel.com reports. The firm owned 22,962 shares of the medical research company’s stock after buying an additional 2,900 shares during the quarter. Thermo Fisher Scientific accounts for 0.5% of New Mexico Educational Retirement Board’s portfolio, making the stock its 26th biggest holding. New Mexico Educational Retirement Board’s holdings in Thermo Fisher Scientific were worth $13,563,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the company. Mutual Advisors LLC increased its stake in Thermo Fisher Scientific by 6.4% during the 3rd quarter. Mutual Advisors LLC now owns 2,023 shares of the medical research company’s stock worth $1,024,000 after acquiring an additional 122 shares during the period. Bamco Inc. NY increased its stake in shares of Thermo Fisher Scientific by 5.0% in the 3rd quarter. Bamco Inc. NY now owns 23,160 shares of the medical research company’s stock valued at $11,723,000 after purchasing an additional 1,101 shares during the last quarter. Morningstar Investment Services LLC increased its stake in shares of Thermo Fisher Scientific by 21.9% in the 3rd quarter. Morningstar Investment Services LLC now owns 764 shares of the medical research company’s stock valued at $384,000 after purchasing an additional 137 shares during the last quarter. Gotham Asset Management LLC lifted its holdings in Thermo Fisher Scientific by 47.5% during the 3rd quarter. Gotham Asset Management LLC now owns 2,654 shares of the medical research company’s stock worth $1,343,000 after buying an additional 855 shares during the period. Finally, Schonfeld Strategic Advisors LLC increased its position in Thermo Fisher Scientific by 54.3% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 12,107 shares of the medical research company’s stock valued at $6,128,000 after buying an additional 4,260 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock traded up $2.22 during trading on Friday, hitting $553.00. The stock had a trading volume of 6,150,885 shares, compared to its average volume of 1,473,906. The firm has a market cap of $211.09 billion, a price-to-earnings ratio of 35.47, a P/E/G ratio of 2.58 and a beta of 0.79. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $603.82. The business’s 50-day moving average is $574.84 and its 200 day moving average is $563.04. The company has a current ratio of 1.70, a quick ratio of 1.33 and a debt-to-equity ratio of 0.68.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, topping the consensus estimate of $4.70 by $0.41. The firm had revenue of $10.35 billion for the quarter, compared to analysts’ expectations of $10.14 billion. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 21.65 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, July 15th. Shareholders of record on Friday, June 14th will be given a dividend of $0.39 per share. The ex-dividend date of this dividend is Friday, June 14th. This represents a $1.56 annualized dividend and a yield of 0.28%. Thermo Fisher Scientific’s payout ratio is 10.01%.

Analyst Ratings Changes

A number of analysts recently commented on the company. Barclays decreased their target price on Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating for the company in a research report on Friday. Evercore ISI boosted their target price on Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a research report on Thursday, April 4th. Citigroup assumed coverage on Thermo Fisher Scientific in a report on Monday, March 18th. They set a “neutral” rating and a $620.00 price objective for the company. Jefferies Financial Group restated a “buy” rating and issued a $650.00 target price (up previously from $600.00) on shares of Thermo Fisher Scientific in a research note on Monday, June 3rd. Finally, JPMorgan Chase & Co. boosted their target price on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research note on Thursday, April 25th. Five equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $607.06.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of the company’s stock in a transaction dated Friday, April 26th. The shares were sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the completion of the sale, the senior vice president now directly owns 13,083 shares in the company, valued at $7,430,359.02. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $572.41, for a total transaction of $5,724,100.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at $70,873,516.56. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction dated Friday, April 26th. The stock was sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the sale, the senior vice president now owns 13,083 shares of the company’s stock, valued at $7,430,359.02. The disclosure for this sale can be found here. Insiders sold a total of 22,000 shares of company stock worth $12,532,780 over the last three months. Company insiders own 0.34% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.